Company intelligence / Profile preview

TiVo

Boston, Massachusetts, United States

Ownership: Private
Employees: ~150
Development stage: Other

Overview

AVEO Oncology, an LG Chem company, is a commercial-stage biopharmaceutical company focused on developing and commercializing targeted therapies for cancer. The company's lead product, Fotivda (tivozanib), is an oral, next-generation vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) approved for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC). AVEO's pipeline also includes candidates targeting the HGF/c-MET pathway and other oncology targets. The company was acquired by LG Chem in early 2023 to serve as its oncology hub in the United States.

Therapeutic areas: Oncology
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Partnerships

Kyowa KirinEUSA PharmaBiodesixCANbridge Pharmaceuticals

Beyond the preview

Go deeper on TiVo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TiVo.

Explore the full profile